[{"id":"52f20fb2-936e-4c1f-b6a3-c2907b2c0c52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02285244","created_at":"2021-01-18T10:46:03.348Z","updated_at":"2025-02-25T15:42:02.535Z","phase":"Phase 2","brief_title":"Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation","source_id_and_acronym":"NCT02285244","lead_sponsor":"James Blachly","biomarkers":" CCND1 • PLCG2","pipe":" | ","alterations":" CCND1 overexpression","tags":["CCND1 • PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotrastaurin (AEB071)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/12/2015","start_date":" 03/12/2015","primary_txt":" Primary completion: 03/12/2015","primary_completion_date":" 03/12/2015","study_txt":" Completion: 03/12/2015","study_completion_date":" 03/12/2015","last_update_posted":"2017-04-05"}]